Human Genome Epidemiology Literature Finder
Pharmacogenomics
Records 1 - 30 (of 821 Records) |
Query Trace: Ribavirin[original query] |
---|
Development and validation of a six-RNA binding proteins prognostic signature and candidate drugs for prostate cancer. Genomics 2020 9 112 (6): 4980-4992. Gao Lei, Meng Jialin, Zhang Yong, Gu Junfei, Han Zhenwei, Wang Xiaolu, Gao Shengl |
Association of cytokine gene polymorphisms with chronic hepatitis C virus genotype 1b infection in Chinese Han population: An observational study. Medicine 2020 9 99 (38): e22362. Jing Ji-Sheng, Wang Zhuo-Qun, Jiang Ying-Kui, Zhang Xin-Yun, Jiang Wei-M |
Diversity of the hepatitis C virus NS5B gene during HIV co-infection. PloS one 2020 8 15 (8): e0237162. Ngwaga Tshegofatso, Kong Ling, Lin Derrick, Schoborg Cassandra, Taylor Lynn E, Mayer Kenneth H, Klein Robert S, Celentano David D, Sobel Jack D, Jamieson Denise J, King Caroline C, Tavis John E, Blackard Jason |
Association of Interleukin 28B Polymorphism with Clearance of Hepatitis C Virus: A Mini Review. Critical reviews in eukaryotic gene expression 2020 8 30 (3): 223-229. Shaheen Mahrukh, Afzal Samia, Khubaib Bushra, Amin Iram, Shahid Muhammad, Idrees Muhamm |
Association between inosine triphosphatase rs1127354 polymorphisms and ribavirin-induced anaemia and outcome in hepatitis C virus-infected patients: A meta-analysis. Journal of clinical pharmacy and therapeutics 2020 Jul . Ma Zhichao, Sun Yi, Du Pengqiang, Li Xinga |
Predictive power of Interleukin-28B gene variants for outcome of Hepatitis C Virus genotype 4 in Egyptians: A systematic review and meta-analysis. Clinics and research in hepatology and gastroenterology 2020 Jul . El-Fattah Mohamed A |
Impact of IL28B gene polymorphism on efficacy and safety of direct acting antivirals in hepatitis C Egyptian patients. International journal of clinical pharmacy 2020 Jul . Ebid Abdel-Hameed Ibrahim Mohamed, Ahmed Ossama Ashraf, Agwa Sara Hassan, Abdel-Motaleb Sara Mohamed, Hagag Radwa Sam |
Impact of Interleukin 28B and ICAM-1 Genetic Polymorphisms on Response to Direct Antiviral Treatment Among HCV Infected Patients. Endocrine, metabolic & immune disorders drug targets 2020 May . Elsheredy Amel G, Almaeen Abdulrahman H, Ghazy Amany A, Helaly Ghada F, Amer Ibrahim, Ghazy Haneen A, Haydara Tam |
Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. Liver international : official journal of the International Association for the Study of the Liver 2020 5 40 (8): 1841-1852. Mangia Alessandra, Milligan Scott, Khalili Mandana, Fagiuoli Stefano, Shafran Stephen D, Carrat Fabrice, Ouzan Denis, Papatheodoridis George, Ramji Alnoor, Borgia Sergio M, Wedemeyer Heiner, Losappio Ruggero, Pérez-Hernandez Francisco, Wick Nicole, Brown Robert S, Lampertico Pietro, Doucette Karen, Ntalla Ioanna, Ramroth Heribert, Mertens Michael, Vanstraelen Kim, Turnes Ju |
Value of IFNL3 genetic polymorphism in the prediction of HCV treatment response to direct-acting antiviral drugs versus interferon therapy. Expert review of anti-infective therapy 2020 May . Ghanem Samar E, El Sabaawy Maha M, Shebl Nashwa, Abdelsameea Eman, Osman Warda, El-Bassal Fathia I, Elgedawy Gamalat A, Elsabaawy Dalia M, Helal Marwa |
Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients. European journal of hospital pharmacy : science and practice 2020 4 27 (e1): e41-e47. Margusino-Framiñán Luis, Cid-Silva Purificación, Rotea-Salvo Sandra, Mena-de-Cea Álvaro, Suárez-López Francisco, Vázquez-Rodríguez Pilar, Delgado-Blanco Manuel, Sanclaudio-Luhia Ana Isabel, Martín-Herranz Isabel, Castro-Iglesias Ángel |
Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2021 Sep 143 112195. Lin Jennifer J, Loucks Catrina M, Trueman Jessica N, Drögemöller Britt I, Wright Galen E B, Yoshida Eric M, Ford Jo-Ann, Lee Samuel S, Kim Richard B, Al-Judaibi Bandar, Schwarz Ute I, Ramji Alnoor, Tam Edward, Ross Colin J, Carleton Bruce |
Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha. Frontiers in cellular and infection microbiology 2021 7 11 656393. da Silva Andréa Marques Vieira, Alvarado-Arnez Lucia Elena, Azamor Tamiris, Batista-Silva Leonardo Ribeiro, Leal-Calvo Thyago, Bezerra Ohanna Cavalcanti de Lima, Ribeiro-Alves Marcelo, Kehdy Fernanda de Souza Gomes, Neves Patrícia Cristina da Costa, Bayma Camilla, da Silva Jane, de Souza Alessandro Fonseca, Muller Marcelo, de Andrade Elisabete Ferreira, Andrade Ana Carolina Magalhães, Dos Santos Eliane Matos, Xavier Janaína Reis, Maia Maria De Lourdes De Sousa, Meireles Rolando Páez, Cuni Hugo Nodarse, Sander Guilherme Becker, Picon Paulo Dornelles, Matos Denise C S, Moraes Milton Ozór |
Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients. Journal of clinical pharmacy and therapeutics 2021 Mar . Hassanien Khalid S, El-Sayed El-Sayed M, Ismail Raed S, Zakarya Zakarya M, Helal Gouda |
Interferon-? inducible protein-10 and interleukin 28B gene polymorphism as predictive markers for genotype 4 hepatitis C virus treatment response. Tropical biomedicine 2020 Dec 37 (4): 1083-1092. Abd El-Maksoud E, Salem A M, Maher A M, Hegazy M G |
Association of macrophage inhibitory factor -1 polymorphisms with antiviral efficacy of type 1b chronic hepatitis C. Molecular and cellular biochemistry 2021 Feb . Ye Songdao, Chen Yao, Lou Xiaoting, Ye Xuanmei, Yang Xunj |
IL28B rs12979860 polymorphism and zinc supplementation affect treatment outcome and liver fibrosis after direct-acting antiviral hepatitis C therapy. Journal, genetic engineering & biotechnology 2021 Oct 19 (1): 150. Attallah Abdelfattah M, Omran Dalia, Abdelrazek Mohamed A, Hassany Mohamed, Saif Sameh, Farid Aza, El Essawey Riham, Ghaffar Muhammad Abdel, Aabdelghany Marwa, Yosry Aym |
Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders. Virology journal 2021 10 18 (1): 199. Sharafi Heidar, Behnava Bita, Azizi-Saraji Alireza, Namvar Ali, Anvar Ali, Salimi Shima, Alavian Seyed Moay |
Pegylated interferon and ribavirin gone but not forgotten in the era of direct-acting antivirals. Minerva pediatrics 2021 1 74 (1): 23-30. Pluta Magdalena, Pokorska-?piewak Maria, Aniszewska Ma?gorzata, Lewandowski Zbigniew, Kowalik-Miko?ajewska Barbara, Marczy?ska Magdale |
Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus. Asian Pacific journal of cancer prevention : APJCP 2021 Oct 22 (10): 3203-3210. Ghanm Samar Ebrahim, Shebl Nashwa Abuel-Fetuh, El Sayed Ibrahim El Tantawy, Abdel-Bary Hamed Mohamed, Saad Basant Farid, Othman Saad War |
ASSESSING PREDICTORS OF DIRECTLY ACTING ANTIVIRALS' FAILURE AS A FURTHER STEP TOWARDS MORE EFFICIENT HCV ELIMINATION PROGRAMS: IL28B (IFNL4) GENE POLYMORPHISM HAS NO ROLE WHILE HIGHER ESTIMATED CREATININE CLEARANCE IS A FORGOTTEN FACTOR. Arquivos de gastroenterologia 2022 7 59 (2): 177-183. Kamal Ahmed, Matta Cecil, Mohsin Heba Akram, Elhadidi Abeer Shawki, Ghazy Ramy Mohamed, Omar Heba Hany, Tahoun Mona, Mohamed Nema Abdelhame |
hsa-miR-17-5p: A Possible Predictor of Ombitasvir/Paritaprevir/Ritonavir?+?Dasabuvir?±?Ribavirin Therapy Efficacy in Hepatitis C Infection. Current microbiology 2022 5 79 (6): 186. Öksüz Zehra, Üçbilek Enver, Serin Mehmet Sami, Yara? Serkan, Temel Gülhan Örekici, Sezgin Orh |
Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy. Pharmaceuticals (Basel, Switzerland) 2022 3 15 (3): . Cusato Jessica, Boglione Lucio, De Nicolò Amedeo, Caviglia Gian Paolo, Mornese Pinna Simone, Ciancio Alessia, Troshina Giulia, Smedile Antonina, Antonucci Miriam, Avataneo Valeria, Palermiti Alice, Mula Jacopo, Manca Alessandra, Cariti Giuseppe, Cantù Marco, Saracco Giorgio Maria, Di Perri Giovanni, D'Avolio Anton |
Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis. Medicine 2022 10 101 (42): e31183. Ren Xiao-Dan, Fu Xue, He Yuan-Qun, Li Chun-Yan, Guo Meng, Qiao M |
Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis. Viruses 2023 7 15 (7): . Pooja Devan, Kai Le Ashley Tiong, Jean Ee Neo, Babu P Mohan, Karn Wijarnpreecha, Yew Chong Steve Tam, Nicola Coppola, Carmen Monica Preda, Yu Jun Wo |
Prediction of response to sofosbuvir-based therapy using serum interleukin-12 and single nucleotide polymorphism of the interleukin 28B gene as predictive factors in HCV positive genotype-4 patients. Medicine 2023 7 102 (28): e34125. Doaa Mohamed Abdelnajid, Ahmed Y Elmowafy, Lionel Rostaing, Marwa T Elrakai |
Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study. Hepatology international 2023 6 . Yu Jun Wong, Sally Tran, Chung-Feng Huang, Yao-Chun Hsu, Carmen Preda, Hidenori Toyoda, Joanne Liu, Dae Won Jun, Charles Landis, Daniel Q Huang, Andrei Gila, Livia Negoita, Satoshi Yasuda, Cheng-Hao Tseng, Pei-Chien Tsai, Haruki Uojima, Akito Nozaki, Makoto Chuma, Masanori Atsukawa, Masatoshi Ishigami, Norio Itokawa, Etsuko Iio, Carla Pui-Mei Lam, Tsunamasa Watanabe, Akira Asai, Keisuke Yokohama, Hiroshi Abe, Masaru Enomoto, Norifumi Kawada, Akihiro Tamori, Dong Hyun Lee, Mi Jung Jun, Son Do, Dang K H Vo, Li Liu, Junyi Li, Fanpu Ji, Wenjun Wang, Yu Li, Xiaozhong Wang, Fen Guo, Qiang Xu, Liang Jing, Qing Ye, Hongying Pan, JiaJie Zhang, Xie Wen, Qi Wang, Hong Ren, Dachuan Cai, Jia Shang, Junping Liu, Chengzheng Lu, Wenqian Zang, Jia Li, Junqi Niu, Mingyuan Zhang, Chao Wu, Rui Huang, Mayumi Maeda, Akiko Nakanishi, Ming-Lun Yeh, Wan-Long Chuang, Jee-Fu Huang, ChiaYen Dai, Toru Ishikawa, Koichi Takaguchi, Tomonori Senoh, Huy N Trinh, Hirokazu Takahashi, Yuichiro Eguchi, Sabrina Xin Zi Quek, Hiroaki Haga, Eiichi Ogawa, Grace Wong, Maria Buti, Shinya Fukunishi, Yoshiyuki Ueno, Man-Fung Yuen, Yasuhito Tanaka, Seng Gee Lim, Ramsey Cheung, Ming-Lung Yu, Mindie H Nguy |
A Retrospective Study of Long-Term Clinical Outcomes in Patients with Chronic Hepatitis C Treated with Interferon and Ribavirin. Discovery medicine 2023 10 35 (178): 868-876. Xiaoting Li, Yi Zhou, Jianning Jiang, Shiyu Long, Guozhen Dong, Man Su, Jijiao Li, Yanchun Wei, Minghua |
Cytokine polymorphisms and genotypic susceptibility of HCV infection in ribavirin response to peg interferon. Tropical biomedicine 2023 10 40 (3): 331-336. Authors are not available |
The severity of depressive symptoms as an independent predictor of Sustained Virological Response during treatment for hepatitis C with pegylated interferon-?2a and oral ribavirin. Psychosomatic medicine 2024 1 . Tomasz Paw?owski, Marek Radkowski, Karol Perlejewski, Tomasz Laskus, Krzysztof Ma?yszcz |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 29, 2024
- Content source: